TGM2 and metabolic dysfunction-associated steatotic liver disease: Since the presence of autoantibodies against TG2 is the hallmark of the CD patients, one can speculate that those antibodies might inhibit TG2 enzymatic activity, causing a greater propensity of these patients to NAFLD development.